Featured 13F manager
Palo Alto Investors LP Palo Alto Investors
Palo Alto, CA 23 processed 13Fs on this site · 2021 Q3–2026 Q2
- $724M
- 52 Positions
- 2026 Q2
- +10.7% QoQ
- Top 5 37.7%
Palo Alto Investors files Palo Alto Investors LP as a Form 13F. The latest book is 2026 Q2 at $724M, up 10.7% QoQ, led by Ptc Therapeutics, Acadia Pharmaceuticals, and Insmed.
Portfolio
top 5 37.7% · top 10 61.3%
- PTC - Ptc Therapeutics 10.4%
- ACAD - Acadia Pharmaceuticals 10.0%
- INSM - Insmed 6.1%
- MIRM - Mirum Pharmaceuticals 5.6%
- ANAB - Anaptysbio 5.6%
- BMRN - Biomarin Pharmaceutical 5.4%
- DYN - Dyne Therapeutics 5.1%
- UTHR - United Therapeutics 4.7%
- IRON - Disc Medicine 4.2%
- BIIB - Biogen 4.2%
- IOVA - Iovance Biotherapeutics 3.0%
- RARE — 2.8%
- Other 32.9%
AUM over time
Book
| INSM - Insmed | 11.86% | Reduce −0.5% | 489,482 | $174.04 | $85M | −2,323 | +$14M |
| FOLD - Amicus | 10.32% | Reduce −3.0% | 5,205,767 | $14.24 | $74M | −162,031 | +$32M |
| PTC - Ptc Therapeutics | 9.56% | Add +4.8% | 903,916 | $75.96 | $69M | +41,303 | +$16M |
| ACAD - Acadia Pharmaceuticals | 9.24% | Add +0.7% | 2,484,031 | $26.71 | $66M | +17,347 | +$14M |
| BMRN - Biomarin Pharmaceutical | 6.17% | Reduce −1.0% | 746,256 | $59.43 | $44M | −7,751 | +$4M |
| ANAB - Anaptysbio | 4.66% | Add +2.5% | 690,032 | $48.48 | $33M | +16,512 | +$13M |
| BIIB - Biogen | 4.50% | Reduce −1.1% | 183,571 | $175.99 | $32M | −2,090 | +$6M |
| DYN - Dyne Therapeutics | 4.01% | Add +16.6% | 1,472,197 | $19.56 | $29M | +209,523 | +$13M |
| UTHR - United Therapeutics | 3.95% | Hold | 58,186 | $487.25 | $28M | — | — |
| IRON - Disc Medicine | 3.51% | Add +41.5% | 317,456 | $79.41 | $25M | +93,156 | +$10M |
| IOVA - Iovance Biotherapeutics | 2.70% | Reduce −6.6% | 7,116,676 | $2.73 | $19M | −501,456 | +$3M |
| NVCR - Novocure | 2.34% | Add +3.4% | 1,298,964 | $12.93 | $17M | +42,805 | +$566K |
| SNDX - Syndax Pharmaceuticals | 2.32% | Add +21.3% | 794,507 | $21.01 | $17M | +139,577 | +$7M |
| Gossamer Bio | 1.93% | Reduce −18.2% | 4,471,592 | $3.10 | $14M | −992,757 | −$509K |
| CMPX - Compass Therapeutics | 1.89% | New | 2,532,419 | $5.37 | $14M | +2,532,419 | +$14M |
| PRTA - Prothena · CL A | 1.76% | Reduce −0.3% | 1,320,510 | $9.55 | $13M | −3,518 | −$312K |
| MIRM - Mirum Pharmaceuticals | 1.72% | Add +141.8% | 156,421 | $78.99 | $12M | +91,721 | +$8M |
| ANNX - Annexon | 1.67% | New | 2,384,192 | $5.02 | $12M | +2,384,192 | +$12M |
| RARE — | 1.48% | Add +24.8% | 461,294 | $23.00 | $11M | +91,763 | −$506K |
| DNLI - Denali Therapeutics | 1.47% | Add +57.2% | 641,239 | $16.51 | $11M | +233,233 | +$5M |
| CDNA - Caredx | 1.25% | Add +51.2% | 478,220 | $18.84 | $9M | +162,016 | +$4M |
| EHTH - Ehealth | 0.98% | Reduce −0.9% | 1,531,429 | $4.60 | $7M | −13,190 | +$387K |
| ALKS - Alkermes | 0.94% | Add +31.9% | 242,560 | $27.98 | $7M | +58,622 | +$1M |
| CAPR — | 0.91% | New | 226,304 | $28.86 | $7M | +226,304 | +$7M |
| TSHA - Taysha Gene Therapies | 0.91% | Reduce −5.0% | 1,183,195 | $5.50 | $7M | −62,838 | +$2M |
| ALGN - Align Technology | 0.90% | Reduce −9.2% | 41,520 | $156.15 | $6M | −4,215 | +$756K |
| AGIO - Agios Pharmaceuticals | 0.81% | Reduce −20.0% | 212,499 | $27.22 | $6M | −52,998 | −$5M |
| BCAX - Bicara Therapeutics | 0.70% | New | 298,575 | $16.83 | $5M | +298,575 | +$5M |
| NUVB - Nuvation Bio · CL A | 0.67% | Reduce −47.3% | 538,079 | $8.96 | $5M | −482,468 | +$1M |
| ACRS - Aclaris Therapeutics | 0.66% | Hold | 1,566,840 | $3.01 | $5M | — | — |
| XENE - Xenon Pharmaceuticals | 0.60% | New | 96,519 | $44.82 | $4M | +96,519 | +$4M |
| TVTX - Travere Therapeutics | 0.59% | Hold | 110,719 | $38.21 | $4M | — | — |
| EW - Edwards Lifesciences | 0.40% | Hold | 33,640 | $85.25 | $3M | — | — |
| NBIX - Neurocrine Biosciences | 0.36% | Hold | 18,117 | $141.83 | $3M | — | — |
| STOK - Stoke Therapeutics | 0.32% | Reduce −31.7% | 72,022 | $31.74 | $2M | −33,405 | −$192K |
| CRSP - Crispr Therapeutics AG | 0.30% | Hold | 41,226 | $52.44 | $2M | — | — |
| BNTX - Biontech Se- | 0.26% | Hold | 19,614 | $95.20 | $2M | — | — |
| ORKA - Oruka Therapeutics | 0.25% | Hold | 59,985 | $30.31 | $2M | — | — |
| BCYC — | 0.22% | Hold | 221,071 | $7.08 | $2M | — | — |
| PYXS - Pyxis Oncology | 0.17% | Hold | 1,037,421 | $1.15 | $1M | — | — |
| ALDX - Aldeyra Therapeutics | 0.16% | Hold | 225,465 | $5.18 | $1M | — | — |
| HUM - Humana | 0.14% | Hold | 3,985 | $256.13 | $1M | — | — |
| INSP - Inspire Medical Systems | 0.11% | New | 8,772 | $92.23 | $809K | +8,772 | +$809K |
| CMPS - Compass Pathways | 0.11% | New | 115,616 | $6.90 | $798K | +115,616 | +$798K |
| URGN - Urogen Pharma | 0.08% | Hold | 24,500 | $23.42 | $574K | — | — |
| ABEO - Abeona Therapeutics | 0.08% | Hold | 108,865 | $5.27 | $574K | — | — |
| PRQR - Proqr Therapeutics | 0.05% | Hold | 188,807 | $2.02 | $381K | — | — |
| Generation Bio | 0.01% | New | 15,047 | $5.68 | $85K | +15,047 | +$85K |
| Akari Therapeutics - | 0.01% | Hold | 146,024 | $0.2890 | $42K | — | — |
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2025 Q3
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| ALNY - Alnylam Pharmaceuticals | 2.73% | Exit | 0 | $456.00 | $15M | −32,320 | −$15M |
| RNAGBP - Avidity Biosciences | 0.89% | Exit | 0 | $43.57 | $5M | −109,831 | −$5M |
| Generation Bio | 0.02% | Exit | 0 | $6.11 | $92K | −15,047 | −$92K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 52 | $724M | +10.7% | RESTATEMENT | 8/19/2026 | 000207367926000102 |
| 2026 Q2 | 52 | $724M | — | RESTATEMENT | 8/18/2026 | 000207367926000101 |
| 2026 Q2 | 52 | $724M | — | 13F-HR | 8/17/2026 | 000207367926000096 |
| 2026 Q1 | 51 | $654M | −8.9% | 13F-HR | 5/15/2026 | 000130692326000004 |
| 2025 Q4 | 49 | $718M | +33.0% | 13F-HR | 2/17/2026 | 000130692326000002 |
| 2025 Q3 | 44 | $540M | +14.9% | 13F-HR | 11/14/2025 | 000130692325000019 |
| 2025 Q2 | 45 | $470M | −10.5% | 13F-HR | 8/14/2025 | 000130692325000016 |
| 2025 Q1 | 44 | $525M | −18.6% | 13F-HR | 5/15/2025 | 000130692325000014 |
| 2024 Q4 | 43 | $645M | −16.2% | 13F-HR | 2/14/2025 | 000130692325000010 |
| 2024 Q3 | 45 | $770M | −10.8% | 13F-HR | 11/14/2024 | 000130692324000012 |
| 2024 Q2 | 39 | $863M | −2.7% | 13F-HR | 8/14/2024 | 000130692324000010 |
| 2024 Q1 | 38 | $887M | −19.9% | 13F-HR | 5/15/2024 | 000130692324000008 |
| 2023 Q4 | 34 | $1.1B | — | RESTATEMENT | 2/15/2024 | 000130692324000007 |
| 2023 Q4 | 34 | $1.1B | +4.7% | 13F-HR | 2/14/2024 | 000130692324000002 |
| 2023 Q3 | 29 | $1.1B | −14.6% | 13F-HR | 11/14/2023 | 000130692323000014 |
| 2023 Q2 | 30 | $1.2B | +2.6% | 13F-HR | 8/14/2023 | 000130692323000012 |
| 2023 Q1 | 30 | $1.2B | +2.9% | 13F-HR | 5/15/2023 | 000130692323000011 |
| 2022 Q4 | 29 | $1.2B | −7.3% | 13F-HR | 2/14/2023 | 000130692323000009 |
| 2022 Q3 | 32 | $1.3B | +10.3% | 13F-HR | 11/14/2022 | 000130692322000016 |
| 2022 Q2 | 33 | $1.1B | −11.3% | 13F-HR | 8/15/2022 | 000130692322000015 |
| 2022 Q1 | 35 | $1.3B | −17.4% | 13F-HR | 5/16/2022 | 000130692322000014 |
| 2021 Q4 | 37 | $1.6B | −5.6% | 13F-HR | 2/14/2022 | 000130692322000004 |
| 2021 Q3 | 42 | $1.7B | — | 13F-HR | 11/15/2021 | 000130692321000026 |
About
Palo Alto Investors LP
23 processed 13Fs on this site · 2021 Q3–2026 Q2